Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiarrhythmic agent |
| gptkbp:approvalYear |
1999 (US)
|
| gptkbp:ATCCode |
C01BD04
|
| gptkbp:brand |
Tikosyn
|
| gptkbp:CASNumber |
115256-11-6
|
| gptkbp:contraindication |
gptkb:congenital_long_QT_syndrome
severe renal impairment concurrent use with verapamil |
| gptkbp:developer |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
10 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C19H27N3O5S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dofetilide
|
| gptkbp:KEGGID |
D07713
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
potassium channel blocker
class III antiarrhythmic |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
3152
CHEMBL1201312 DB00204 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:torsades_de_pointes
dizziness headache ventricular arrhythmia |
| gptkbp:UNII |
8L70Q75FXE
|
| gptkbp:usedFor |
gptkb:atrial_fibrillation
atrial flutter |
| gptkbp:bfsParent |
gptkb:Atrial_Flutter
|
| gptkbp:bfsLayer |
7
|